ArticleAnnals of surgical oncology2026
KRAS and TP53 Circulating Tumor DNA are Prognostic in Localized Pancreatic Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04616131 (Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) carries high mortality despite neoadjuvant chemotherapy (NAC) and surgical resection, creating an urgent need for prognostic biomarkers to guide treatment. We aimed to determine whether circulating tumor DNA (ctDNA) detected by next-generation sequencing (NGS) predicts survival in patients with localized PDAC.
methodsPatients with localized PDAC were prospectively enrolled at an academic institution between October 2020 and November 2024 (NCT04616131). Patients underwent next-generation sequencing (NGS), with blood samples collected at diagnosis, post-NAC, and post-resection. Total, KRAS-specific, and TP53-specific ctDNA detection rates were quantified. Associations with overall survival (OS) were evaluated by using Kaplan-Meier curves and multivariable Cox proportional hazards models adjusting for key clinical covariates.
resultsWe collected 219 samples from 113 patients across three treatment timepoints. Mutant KRAS ctDNA was detected in 19% at diagnosis, decreased to 4.6% after NAC (19% vs. 4.6%, p = 0.010), and was detected in 8.2% after resection. Total ctDNA detection at diagnosis predicted lower odds of proceeding to resection (adjusted odds ratio [aOR] 0.38, 95% confidence interval [CI] 0.14-0.97, p = 0.049). KRAS and TP53 co-occurrence at diagnosis independently predicted shorter OS (adjusted hazard ratio 5.66, 95% CI 2.43-13.18, p < 0.001). Increases in total ctDNA maximum variant allele frequency over treatment also predicted shorter OS (adjusted hazard ratio 1.14, 95% CI 1.01-1.28, p = 0.028).
conclusionsIn a large prospective cohort, tumor-agnostic NGS-based ctDNA detection demonstrated prognostic value in patients with localized PDAC undergoing NAC and surgery. These findings suggest ctDNA can inform treatment monitoring and risk stratification, supporting further evaluation in larger, multi-center studies to guide clinical decision-making.
Indexed as
Identifiers
42649442What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.